SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that data from clinical trials of its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), will be presented at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 34th Annual Regional Anesthesia Meeting in Phoenix, Arizona on April 30, 2009 and at the Society of Hospital Medicine (SHM) Annual Meeting in Chicago, Illinois on May 16, 2009.
At the ASRA meeting, data from three completed clinical trials of Acetavance will be presented in poster presentations, as follows:
Data from two other completed clinical trials of Acetavance will be presented in poster presentations at the SHM meeting, as follows:
Top line data from each of these clinical trials has been previously disclosed by Cadence, with the exception of data from Study 352, which was recently completed.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.
Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.
Contacts: William R. LaRue SVP & Chief Financial Officer Cadence Pharmaceuticals, Inc. 858-436-1400
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved